Given the relatively high frequency (∼90%) of KRAS mutation in pancreatic cancer, we chose CAPAN-2 and HPAC tumor xenografts harboring distinct mutations in KRAS, namely G12D and G12V, respectively for the combination studies. Here, KRAS is linked to neoplasm.